

1       **Spinal Cord Motor Neuron Phenotypes and Polygenic Risk**  
2               **Scores in Sporadic Amyotrophic Lateral Sclerosis:**  
3       **Deciphering the Disease Pathology and Therapeutic Potential**  
4               **of Ropinirole Hydrochloride**

5               Chris Kato,<sup>1</sup> Satoru Morimoto,<sup>1,†</sup> Shinichi Takahashi,<sup>1,2</sup> Shinichi Namba,<sup>3</sup> Qingbo S.  
6                               Wang,<sup>3,4,5</sup> Yukinori Okada,<sup>3,4,5,6,7,8</sup> Hideyuki Okano<sup>1,†</sup>

7       <sup>†</sup>**Co-corresponding author**

8       **Author affiliations:**

9       <sup>1</sup>Department of Physiology, Keio University School of Medicine, Tokyo, Japan.

10       <sup>2</sup>Department of Neurology and Cerebrovascular Medicine, Saitama Medical University  
11       International Medical Center, Saitama, Japan.

12       <sup>3</sup>Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita,  
13       Japan.

14       <sup>4</sup>Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC),  
15       Osaka University, Suita, Japan.

16       <sup>5</sup>Department of Genome Informatics, Graduate School of Medicine, The University of  
17       Tokyo, Tokyo, Japan.

18       <sup>6</sup>Integrated Frontier Research for Medical Science Division, Institute for Open and  
19       Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.

20       <sup>7</sup>Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita,  
21       Japan.

- 1 <sup>8</sup>Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences,
- 2 Yokohama, Japan.

# 1 **ABSTRACT**

2 This study investigated the genetic factors associated with the onset of amyotrophic lateral  
3 sclerosis (ALS) and the mechanism of action of Ropinirole hydrochloride (ROPI) in ALS  
4 treatment. Firstly, ALS is a neurodegenerative disease characterized by the degeneration of  
5 both upper and lower motor neurons (MNs), and identifying the genetic factors of sporadic  
6 ALS (SALS) has been challenging. However, ALS-like phenotypes have been observed in  
7 induced pluripotent stem cell-derived lower MNs (iPSC-LMNs) of SALS patients, suggesting  
8 a polygenic contribution to SALS pathogenesis, and ROPI has emerged as a novel therapeutic  
9 candidate for ALS treatment. Moreover, recent genome-wide association studies (GWAS)  
10 have suggested an association between high levels of blood total cholesterol (bTC) and ALS.  
11 The study aimed to combine iPSC-LMN phenotypes and polygenic risk scores (PRS) to  
12 quantify the genetic background of patients and analyze the mechanism of action of ROPI in  
13 ALS treatment. Twenty SALS patients were included in the study, and iPSC-LMN  
14 phenotypes, PRS for 58 quantitative traits, and ALS were calculated. The results indicated  
15 that patients with a higher PRS for bTC showed changes in iPSC-LMN phenotypes,  
16 particularly a higher response to ROPI. Additionally, a correlation was observed between  
17 bTC levels and the expression of cholesterol biosynthesis (CB) enzymes in MNs, suggesting  
18 their involvement in the pathogenesis of SALS. Furthermore, the study compared the liver  
19 and spinal cord expression of CB enzymes and found a correlation between bTC levels and  
20 CB enzyme expression, particularly in MNs, which may partly explain the MN-specific  
21 pathogenesis of SALS. In conclusion, the study suggests that high bTC levels and increased  
22 CB activity may contribute to the pathogenesis of SALS, and CB suppression may be a  
23 potential therapeutic strategy for ALS, supported by the mechanism of action of ROPI in  
24 ALS treatment.

# 1 INTRODUCTION

2 Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by both  
3 upper and lower motor neuron (MN) degeneration. Approximately 90% of ALS patients have  
4 sporadic ALS (SALS). Thus, identifying the genetic factors of SALS is difficult. However,  
5 lower MNs (LMNs), including spinal MNs, that derive from induced pluripotent stem cells  
6 (iPSC-LMNs) in SALS patients exhibit ALS-like phenotypes,<sup>1</sup> such as reduced neurite length  
7 (NL), suggesting a polygenic contribution to SALS pathogenesis.

8 Drug screening using iPSC-LMNs recently identified ropinirole hydrochloride (ROPI) as a  
9 novel therapeutic candidate for ALS.<sup>1</sup> A clinical trial of ROPI (the Ropinirole Hydrochloride  
10 Remedy for Amyotrophic Lateral Sclerosis [ROPALS] trial) involving 20 SALS patients  
11 suggested that ROPI inhibits the pathological progression in ALS development.<sup>2</sup> Furthermore,  
12 our reverse translational study in the ROPALS trial revealed that patients who had  
13 iPSC-LMNs that responded strongly to ROPI showed greater clinical efficacy in the trial.<sup>2</sup>  
14 This suggests that iPSC-MN phenotypes reflect drug responsiveness in SALS patients.

15 Recent genome-wide association studies (GWASs) have uncovered genetic predispositions  
16 for various traits in individuals. A recent GWAS in ALS patients suggested that the mutations  
17 associated with high levels of blood total cholesterol (bTC) play a causal role in ALS  
18 development.<sup>3</sup> The polygenic risk score (PRS) is a quantitative measure that is obtained by  
19 summing the small effects of each risk variant identified by GWASs and is widely used to  
20 predict diverse traits in individuals.

21 In the present study, we aimed to identify the genetic factors in the development of SALS and  
22 the mechanism underlying the anti-ALS effect of ROPI by combining two indices that reflect  
23 genetic predisposition: the phenotype of iPSC-LMNs and the PRS (Fig. 1A).

1

## 2 **METHODS**

3 This study included 20 SALS patients who participated in the ROPALS trial. We used a  
4 dataset obtained for the ROPALS trial,<sup>2</sup> which involved measuring the NL and the  
5 transcriptome of iPSC-LMNs with and without ROPI administration (Fig. 1A). We calculated  
6 both the untreated NL (uNL) and the degree of improvement of NL by ROPI (diNL<sub>ROPI</sub>).  
7 Additionally, we calculated PRSs for 58 quantitative traits and ALS (Supplementary Table 1).  
8 Using public data, we also analyzed the liver-cervical spinal cord (SC) comparison of  
9 expression quantitative trait loci (eQTLs) effect sizes, and the transcriptome in various cell  
10 types in the lumbar SC.

11 The public data sources are detailed in Supplementary Table 2. More detailed methodological  
12 information is provided in the Supplementary Methods.

13

## 14 **RESULTS**

15 The allele frequencies of SALS patients in the ROPALS trial were highly similar to the  
16 Japanese allele frequency panel ( $P < 0.0001$ ,  $R = 0.9740$  [0.9740 0.9741]), which confirmed  
17 appropriate sequence determination (Fig. 1B). Moreover, the iPSC-LMN phenotypes (i.e.,  
18 uNL and diNL<sub>ROPI</sub>) showed a weak non-significant correlation with the PRS of ALS, which  
19 suggests that the phenotypes reflect the genetic background in ALS (Supplementary Fig. 1A).

20 The correlation analysis between iPSC-LMN phenotypes and the PRSs for 58 quantitative  
21 traits and ALS revealed that the greatest difference in correlation coefficients between uNL

1 and  $\text{diNL}_{\text{ROPI}}$  was observed in bTC (Figure 1C; Supplementary Table 1). Patients with a  
2 higher bTC PRS tended to have shorter uNL ( $P = 0.2019$ ,  $R = -0.2980$  [-0.6542 0.1665]) and  
3 greater  $\text{diNL}_{\text{ROPI}}$  ( $P = 0.0343$ ,  $R = 0.4751$  [0.0413 0.7582]; Fig. 1D). Moreover, patients with  
4 higher expression of cholesterol biosynthesis (CB) enzymes (Supplementary Table 3) in  
5 iPSC-LMNs had greater  $\text{diNL}_{\text{ROPI}}$  ( $P = 0.0475$ ,  $R = 0.4482$  [0.0071 0.7433]; Fig. 1D).

6 bTC levels generally reflect CB levels in the liver, whereas cholesterol levels in the SC are  
7 independent of systemic circulation. Therefore, we compared the sizes of the effect of eQTLs  
8 on CB enzyme expression in the liver and cervical SC using the genotype-tissue expression  
9 project data, which showed high conservation ( $P < 0.0001$ ,  $R = 0.5924$  [0.5484 0.6332]; Fig.  
10 1E).

11 The cell-type specificity of CB in the SC was examined using pseudo-bulk differential  
12 expression analysis, which was based on public single-nucleus ribonucleic acid sequencing  
13 data of the human lumbar SC (Fig. 1F and G). The marker genes of each cell type confirmed  
14 that the cell types were appropriately identified (Supplementary Fig. 1B). Results showed that  
15 CB enzyme expression in MNs was higher than that in astrocytes (ASs) or non-MNs (nMNs)  
16 and similar to that in oligodendrocytes (OLs; MNs vs. ASs:  $P < 0.0001$ , vs. nMNs:  $P <$   
17  $0.0001$ , vs. OLs:  $P = 0.6072$ ; Fig. 1H and I).

18

## 19 **DISCUSSION**

20 Our findings suggested that individuals with a genetic predisposition for a high level of bTC  
21 may also have increased CB activity in the liver, SC, and ultimately MNs, which may result  
22 in an ALS-like phenotype of reduced NL in iPSC-LMNs.

1 Given that the genetic factors associated with high bTC levels play a causal role in the  
2 development of SALS, as reported by a large-scale GWAS in ALS patients,<sup>3</sup> it is plausible  
3 that CB hyperactivity in MNs (determined by genetic background) contributes to the  
4 development of SALS. It has previously been reported that CB hyperactivity increases the  
5 presence of cholesterol esters, a neurotoxic metabolite, and this has been proposed as a  
6 mechanism underlying MN death in ALS.<sup>4</sup> Indeed, elevated levels of cholesterol and  
7 cholesterol esters have been observed in the spinal fluid of SALS patients.<sup>4,5</sup> Furthermore,  
8 increased CB activity in the mouse SC has been shown to produce ALS-like symptoms.<sup>4</sup> The  
9 enhanced CB activity in MNs compared with nMNs suggests cell-type specificity, which  
10 could partly explain the MN-specific pathogenesis of SALS.

11 In contrast, a higher PRS for bTC was associated with a better response to ROPI *in vitro*.  
12 Because ROPI has been shown to suppress CB enzyme expression in iPSC-LMNs,<sup>2</sup> the  
13 suppression of CB at the MN level may be a potential anti-ALS mechanism of ROPI.

14 In conclusion, the combined analysis of iPSC-LMN phenotypes and PRSs to quantify the  
15 genetic background of patients showed that increased CB in MNs is pivotal for SALS  
16 pathology and its suppression may be the mechanism underlying the anti-ALS effect of ROPI.  
17 Thus, CB suppression may be a viable strategy for the treatment of SALS.

18

19 **Correspondences to:**

20 Hideyuki Okano, MD, PhD

21 Dean, Keio University Graduate School of Medicine

22 Professor, Department of Physiology

1 Full address: Department of Physiology, Keio University School of Medicine, 35  
2 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

3 E-mail: hidokano@keio.jp

4 Tell: +81-3-5363-3747

5

6 Satoru Morimoto, MD, PhD

7 Instructor, Department of Physiology

8 Department of Physiology, Keio University School of Medicine, 35 Shinanomachi,  
9 Shinjuku-ku, Tokyo, 160-8582, Japan

10 Email: satoru\_morimoto@keio.jp

11 Tell: +81-3-5363-3747

12

### 13 **Acknowledgements**

14 We thank the coordinators, staff, physicians, and participants of the ROPALS trial. We are  
15 also grateful to Shiho Nakamura, Fumiko Ozawa, Naoki Kobayashi, Hiroya Kobayashi, Yuki  
16 Oguma (Keio University), and Selena Setsu (University of Tokyo). We extend our special  
17 thanks to Professor Hiroshi Nishihara (Genomics Unit, Keio Cancer Center, Keio University  
18 Hospital) for his invaluable advice on genomic analysis.

19



1 **Contributors**

2 C.K., S.M. and S.T. designed the study and acquired samples from patients. C.K. analysed  
3 the data and performed statistical analyses. C.K., S.M., S.T., S.N., Q.S.W., Y.O. and H.O.  
4 contributed to the interpretation of the results. S.T., S.N., Q.S.W., Y.O. and H.O. provided  
5 supervision. C.K. and S.M. wrote the manuscript, and all authors corrected the manuscript  
6 and collectively made the decision to submit for publication.

7

8 **Funding**

9 This study was supported by the grant support from Japan Society for the Promotion of  
10 Science (JSPS) (KAKENHI Grant No. JP21H05278 and JP22K15736 to S.M., JP22K07500  
11 to S.T. and JP20H00485 to H.O.), Japan Agency for Medical Research and Development  
12 (AMED) (Grant No. JP22ek0109616, JP23bm1123046, JP23kk0305024 to S.M.,  
13 JP21wm0425009, JP22bm0804003, JP22ek0109616, JP23bm1423002 to H.O.), and Miyata  
14 Yukihiro Memorial ALS Research Grant Foundation to S.M., research grant of Kanae  
15 Foundation for the Promotion of Medical Science to S.M., Okasan-Kato Foundation Research  
16 Grant to S.M. and Yoshio Koide Grant, Japan ALS Association to S.M., and Daiichi Sankyo  
17 Foundation of Life Science to S.M.

18

19 **Competing interests**

20 Hideyuki Okano reports grants and personal fees as a Chief Scientific Officer from K Pharma,  
21 Inc. during the conduct of the study; personal fees from Sanbio Co. Ltd., outside the  
22 submitted work; In addition, Hideyuki Okano has a patent on a therapeutic agent for  
23 amyotrophic lateral sclerosis and composition for treatment licensed to K Pharma, Inc.

1 Q.S.W is currently an employee of Calico Life Science LLC. Involvement in the presented  
2 research was prior to the affiliation. The other authors have declared that no conflict of  
3 interest exists.

4

#### 5 **Patient consent for publication**

6 Not applicable.

7

#### 8 **Ethics approval**

9 This study was approved by the Institutional Review Board of Keio University School of  
10 Medicine (approval No. 20080016), and written informed consent was obtained from the  
11 participants.

12

## 13 **REFERENCES**

- 14 1. Fujimori K, Ishikawa M, Otomo A, et al. Modeling sporadic ALS in iPSC-derived  
15 motor neurons identifies a potential therapeutic agent. *Nat Med.*  
16 2018;24(10):1579-1589. doi:10.1038/s41591-018-0140-5
- 17 2. Morimoto S, Takahashi S, Ito D, et al. Phase 1/2a clinical trial in ALS with ropinirole, a  
18 drug candidate identified by iPSC drug discovery. *Cell Stem Cell.*  
19 2023;30(6):766-780.e9. doi:10.1016/j.stem.2023.04.017
- 20 3. van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant  
21 association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct

1 genetic architectures and neuron-specific biology. *Nat Genet.* 2021;53(12):1636-1648.  
2 doi:10.1038/s41588-021-00973-1

3 4. Dodge JC, Jensen EH, Yu J, et al. Neutral Lipid Cacostasis Contributes to Disease  
4 Pathogenesis in Amyotrophic Lateral Sclerosis. *J Neurosci.* 2020;40(47):9137-9147.  
5 doi:10.1523/JNEUROSCI.1388-20.2020

6 5. Abdel-Khalik J, Yutuc E, Crick PJ, et al. Defective cholesterol metabolism in  
7 amyotrophic lateral sclerosis. *J Lipid Res.* 2017;58(1):267-278.  
8 doi:10.1194/jlr.P071639

9

## 10 **FIGURE LEGEND**

11 **Figure 1. Analysis of lower motor neuron derived from induced pluripotent stem cell**  
12 **(iPSC-LMN) phenotypes and polygenic risk scores (PRSs) in sporadic amyotrophic**  
13 **lateral sclerosis (SALS) patients revealed that increased cholesterol biosynthesis (CB) in**  
14 **LMNs is vital to SALS pathology, and the suppression of CB by ropinirole**  
15 **hydrochloride (ROPI) is a key treatment strategy.**

16 **(A)** Schematic diagram of the study.

17 **(B)** Comparison of allele frequencies between SALS patients from the Ropinirole  
18 hydrochloride remedy for amyotrophic lateral sclerosis (ROPALS) trial ( $N = 20$ ) and the  
19 Japanese allele frequency panel (Tohoku Medical Megabank Organization [ToMMo],  
20 54KJPN).

21 **(C) (Left)** Results of the Pearson's correlation analyses between the PRSs for 58 quantitative  
22 traits and the iPSC-LMN phenotypes (untreated neurite length [uNL] and degree of

1 improvement in neurite length by ROPI [ $diNL_{ROPI}$ ]). Each plot represents the correlation  
2 coefficient (amyotrophic lateral sclerosis [ALS]: salmon pink, 58 quantitative traits:  
3 blue). Differences in correlation coefficients between the PRSs (for ALS and 58  
4 quantitative traits) and iPSC-LMN phenotypes (uNL and  $diNL_{ROPI}$ ; which reflects the  
5 extent of ALS pathology and the degree of improvement following ROPI administration,  
6 respectively) are shown in shades of blue (the brighter the trait, the more ALS pathology  
7 is exacerbated by high PRS for that trait while it improves with ROPI administration).  
8 **(Right)** Differences in correlation coefficients between the PRSs (for ALS and 58  
9 quantitative traits) and iPSC-LMN phenotypes (uNL and  $diNL_{ROPI}$ ) are shown on the  
10 vertical axis, and the absolute values of each correlation coefficient are shown on the  
11 horizontal axis. The left half shows the absolute values of the correlation coefficients for  
12 uNL, and the right half shows those for  $diNL_{ROPI}$ . Orange circles indicate traits with  
13 positive correlations, and light blue circles indicate traits with negative correlations.

14 **(D)** Results of the Pearson's correlation analyses between the PRS for blood total cholesterol  
15 (bTC) and iPSC-LMN phenotypes (uNL and  $diNL_{ROPI}$ ; upper and middle graph). Results  
16 of the Pearson's correlation analysis between CB enzyme expression in iPSC-MNs and  
17 its  $diNL_{ROPI}$  (lower graph).

18 **(E)** Comparison of tissue-specific effect sizes of the liver and cervical spinal cord (SC) for  
19 expression quantitative trait loci (eQTLs) visualizing the expression levels of CB  
20 enzymes (Pearson's correlation test). Each plot represents each eQTL.

21 **(F)** Uniform manifold approximation and projection (UMAP) of human lumbar SC cells. We  
22 used the same cell-type identification method as that used in the original paper.

23 **(G)** Overview of pseudo-bulk differential expression analysis.

1 **(H)** Volcano plots showing the results of the pseudo-bulk differential expression analysis,  
2 compared by cell type (MNs, astrocytes [ASs], non-MNs [nMNs], and oligodendrocytes  
3 [OLs]). From left to right, results for ASs vs. MNs, nMNs vs. MNs, and OLs vs. MNs  
4 are presented. Fold changes are calculated relative to MNs.

5 **(I)** Graphs showing relative expression of CB pathway enzymes by cell-type comparisons  
6 (MNs, ASs, nMNs, and OLs). Each plot represents the expression index of CB enzymes  
7 per pseudo-bulk. Coloured plots represent the mean expression index for each cell type.  
8 Error bars represent standard errors of the mean.

9 SALS, sporadic amyotrophic lateral sclerosis; iPSC-LMN, lower motor neuron derived from  
10 induced pluripotent stem cell; ROPI, ropinirole hydrochloride; NL, neurite length;  $\text{diNL}_{\text{ROPI}}$ ,  
11 degree of improvement of NL by ROPI; uNL, untreated NL; PRS, polygenic risk score;  
12 DNA-seq, deoxyribose nucleic acid sequence; SNV, single nucleotide variant; adj. *P*-value,  
13 adjusted *P*-value; bTC, blood total cholesterol; HDL-C, high-density-lipoprotein cholesterol;  
14 APTT, activated partial thromboplastin time; CRP, C-reactive protein; ALS, amyotrophic  
15 lateral sclerosis; Mono, monocyte count; Cl, chloride; IVS, interventricular septum thickness  
16 (echocardiographic); RWT, relative wall thickness (echocardiographic); vs., versus; GTE<sub>x</sub>,  
17 genotype-tissue expression; eQTL, expression quantitative trait loci; OPC, oligodendrocyte  
18 precursor cell; UMAP, uniform manifold approximation and projection; RNA, ribonucleic  
19 acid; snRNA-seq, single-nucleus RNA sequence; ASs, astrocytes; OLs, oligodendrocytes;  
20 exp., expression.

